Table 3e. Dosing Regimens for the Drugs Recommended for the Treatment of MIS-C
Last Updated: February 29, 2024
Dosing Regimens For infants, children, and adolescents unless otherwise specified. The doses listed are for FDA-approved indications for other diseases or from reported experiences or clinical trials. | Adverse Events | Monitoring Parameters | |
---|---|---|---|
Intravenous Immunoglobulin | IVIG 2 g/kg IBW IV (up to a maximum total dose of 100 g) In the event of cardiac dysfunction or fluid overload, consider administering IVIG in divided doses (i.e., IVIG 1 g/kg IBW IV, up to 50 g daily for 2 doses). |
|
|
Methylprednisolone | Methylprednisolone 1–2 mg/kg IV every 12 hours Intensification immunomodulatory therapy: If the patient does not respond to 1–2 mg/kg IV every 12 hours, increase the dose to 10–30 mg/kg/day IV for 1–3 days (up to a maximum of 1,000 mg/day). Glucocorticoids should be tapered gradually after signs of clinical improvement. The duration of the taper will depend on the patient’s clinical status. |
|
|
Anakinra | Anakinra 5–10 mg/kg/day IV (preferred) or SUBQ in 1–4 divided doses |
|
|
Infliximab | Infliximab 5–10 mg/kg IV for 1 dose |
|
|
Aspirin | Aspirin 3–5 mg/kg PO once daily (up to a maximum of 81 mg) |
|
|
Enoxaparin | For Prophylaxis Aged >2 Months to <18 Years
For Treatment
|
|
|
Key: AE = adverse event; BMP = basic metabolic panel; CBC = complete blood count; FDA = Food and Drug Administration; IBW = ideal body weight; IV = intravenous; IVIG = intravenous immunoglobulin; LFT = liver function test; MIS-C = multisystem inflammatory syndrome in children; PO = oral; SCr = serum creatinine; SUBQ = subcutaneous |